Compare MELI & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MELI | REGN |
|---|---|---|
| Founded | 1999 | 1988 |
| Country | Uruguay | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.0B | 77.5B |
| IPO Year | 2007 | 1995 |
| Metric | MELI | REGN |
|---|---|---|
| Price | $1,545.67 | $703.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 25 |
| Target Price | ★ $2,666.47 | $830.16 |
| AVG Volume (30 Days) | 441.4K | ★ 667.2K |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.55% |
| EPS Growth | 4.54 | ★ 8.19 |
| EPS | ★ 8.23 | 6.75 |
| Revenue | ★ $28,893,000,000.00 | $5,872,227,000.00 |
| Revenue This Year | $36.23 | $12.45 |
| Revenue Next Year | $24.20 | $10.13 |
| P/E Ratio | ★ $41.40 | $105.71 |
| Revenue Growth | ★ 39.06 | 20.82 |
| 52 Week Low | $1,593.21 | $476.49 |
| 52 Week High | $2,645.22 | $821.11 |
| Indicator | MELI | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 29.71 | 40.58 |
| Support Level | N/A | $679.36 |
| Resistance Level | $2,498.41 | $783.87 |
| Average True Range (ATR) | 55.03 | 19.63 |
| MACD | -26.26 | -1.64 |
| Stochastic Oscillator | 0.99 | 35.02 |
MercadoLibre is the largest e-commerce marketplace in Latin America, with more than 120 million unique active buyers and 1 million active sellers at the end of 2025. The company is roughly split between its e-commerce business, which includes its fulfillment and advertising services, and its fintech segment, which comprises its rapidly expanding payment and digital wallet platform (Mercado Pago) and its lending business (Mercado Credito). While the company operates in 18 countries, its primary markets are Brazil, Argentina, and Mexico, which account for more than 95% of its revenue.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).